Showing results (31-40 of 96) with videos related to
Sort By:
Pageof 10
Journal of the American College of Cardiology|September 14, 2010
Inhibitory effects of ticagrelor compared with clopidogrel on platelet function in patients with acute coronary syndromes: the PLATO (PLATelet inhibition and patient Outcomes) PLATELET substudyRobert F Storey, Dominick J Angiolillo, Shankar B Patil, et al.Journal of the American College of Cardiology|November 6, 2007
Inhibition of platelet aggregation by AZD6140, a reversible oral P2Y12 receptor antagonist, compared with clopidogrel in patients with acute coronary syndromesRobert F Storey, Steen Husted, Robert A Harrington, et al.Stroke|October 4, 2012
Bleeding during treatment with aspirin versus apixaban in patients with atrial fibrillation unsuitable for warfarin: the apixaban versus acetylsalicylic acid to prevent stroke in atrial fibrillation patients who have failed or are unsuitable for vitamin K antagonist treatment (AVERROES) trialGreg C Flaker, John W Eikelboom, Olga Shestakovska, et al.American Heart Journal|April 1, 2009
Comparison of ticagrelor, the first reversible oral P2Y(12) receptor antagonist, with clopidogrel in patients with acute coronary syndromes: Rationale, design, and baseline characteristics of the PLATelet inhibition and patient Outcomes (PLATO) trialStefan James, Axel Akerblom, Christopher P Cannon, et al.European Heart Journal|September 30, 2015
Growth differentiation factor-15 level predicts major bleeding and cardiovascular events in patients with acute coronary syndromes: results from the PLATO studyEmil Hagström, Stefan K James, Maria Bertilsson, et al.Lancet (London, England)|August 31, 2010
Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trialLars Wallentin, Stefan James, Robert F Storey, et al.Clinical Chemistry|May 24, 2013
Cystatin C- and creatinine-based estimates of renal function and their value for risk prediction in patients with acute coronary syndrome: results from the PLATelet Inhibition and Patient Outcomes (PLATO) studyAxel Åkerblom, Lars Wallentin, Anders Larsson, et al.Europace : European Pacing, Arrhythmias, and Cardiac Electrophysiology : Journal of the Working Groups on Cardiac Pacing, Arrhythmias, and Cardiac Cellular Electrophysiology of the European Society of Cardiology|October 8, 2015
Substantial differences in initiation of oral anticoagulant therapy and clinical outcome among non-valvular atrial fibrillation patients treated in inpatient and outpatient settingsAnders Pretzmann Mikkelsen, Morten Lock Hansen, Jonas Bjerring Olesen, et al.American Heart Journal|March 31, 2015
An open-label, randomized, controlled, multicenter study exploring two treatment strategies of rivaroxaban and a dose-adjusted oral vitamin K antagonist treatment strategy in subjects with atrial fibrillation who undergo percutaneous coronary intervention (PIONEER AF-PCI)C Michael Gibson, Roxana Mehran, Christoph Bode, et al.European Heart Journal. Acute Cardiovascular Care|April 6, 2016
Outcomes after planned invasive or conservative treatment strategy in patients with non-ST-elevation acute coronary syndrome and a normal value of high sensitivity troponin at randomisation: A Platelet Inhibition and Patient Outcomes (PLATO) trial biomarker substudyEvangelos Giannitsis, Lars Wallentin, Stefan K James, et al.Pageof 10